RESEARCH MONOGRAPH · KDC-MN-278

Exemestane

May 9, 2026 Kodiac biolabs Research Revised May 30, 2026 3 min read

Our opinion on this compound

82/100

Steroidal suicide AI with a different pharmacology profile that genuinely matters for some uses

Exemestane is the steroidal aromatase inhibitor in the third-generation lineup, and the steroidal nature is the whole reason it's clinically and pharmacologically distinct from anastrozole and letrozole. Pharmacia's androstenedione analog with a methylene substitution at the 6-position binds aromatase as a substrate analog and then irreversibly inactivates the enzyme through a suicide mechanism. New aromatase activity has to wait for new protein synthesis, which gives exemestane fundamentally different pharmacokinetics from the reversible non-steroidal AIs.

The mechanism story has practical consequences. Exemestane has a relatively short half-life (about 24 hours) but the pharmacodynamic effect is much longer because the aromatase enzyme has to be resynthesized. That mismatch between pharmacokinetics and pharmacodynamics means dosing flexibility is different from the non-steroidal AIs. It also means that as a research tool, exemestane and a non-steroidal AI like anastrozole behave differently even when they're producing similar levels of estrogen suppression.

The androgenic side of the profile is the other meaningful difference. The active metabolite 17-hydroexemestane has modest androgenic activity at AR, which is why exemestane has a slightly different adverse effect profile (less bone loss in some comparisons, occasionally androgenic symptoms in long-term use) than the non-steroidal AIs. The androgenic effect isnt large but it's real and worth knowing for research design.

What we like is the differentiated mechanism for research use. If you want to ask whether the effects of aromatase inhibition are entirely mediated by estrogen suppression or whether residual androgen elevation matters separately, the comparison between exemestane (steroidal, with androgenic metabolite) and letrozole or anastrozole (non-steroidal, no androgenic activity) is one of the cleaner ways to dissect that question.

The clinical evidence base is solid. The EXACT trial established exemestane in adjuvant breast cancer therapy after initial tamoxifen, and the MAP3 prevention trial showed efficacy in postmenopausal high-risk women. The data is somewhat less voluminous than for letrozole and anastrozole but reproducible.

Sourcing is good. Off-patent, multiple generics globally, pharmacopoeial standards. Research-grade material is straightforward.

Workhorse with the underappreciated angle being the distinct steroidal mechanism. Reliability is high, the mechanism is textbook for the suicide-inhibitor class, and the differentiated pharmacology genuinely matters for some research questions.

Evidence: 88
Mechanism: 90
Reliability: 85
Safety: 75
Sourcing: 88
Value: 82
Signal: 72
Staying power: 78

Plain-language summary Intrigue 60 / 100

Exemestane (Aromasin) is the third major aromatase inhibitor, approved in 1999. It is mechanistically distinct from anastrozole and letrozole: rather than competitively binding aromatase, it is a substrate analog that the enzyme starts to process but cannot release, becoming permanently inactivated (a so-called suicide inhibitor). Recovery requires the body to make new aromatase, so the effect outlasts any individual dose. Estradiol suppression is comparable to letrozole. Because it has a steroid backbone, exemestane retains weak androgenic activity, which some users perceive as a side effect (acne, oily skin) and others as a feature. Used in postmenopausal breast cancer and off-label by steroid users. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Steroidal (suicide) aromatase inhibitor

A steroidal mechanism-based aromatase inhibitor; irreversibly inactivates aromatase by covalent suicide adduction.

Abstract

Exemestane (6-methylenandrosta-1,4-diene-3,17-dione; CAS 107868-30-4; molecular formula C20H24O2; molecular weight 296.40) is a steroidal third-generation aromatase inhibitor developed at Pharmacia (now Pfizer) and approved by the FDA in 1999 under the trade name Aromasin. Distinct from anastrozole and letrozole by mechanism: exemestane is a substrate analog of androstenedione that aromatase begins to process but cannot release, producing irreversible covalent inactivation of the enzyme. Recovery of aromatase activity requires de novo enzyme synthesis. Plasma estradiol suppression is comparable to anastrozole (approximately 85 to 95 percent at 25 mg). The steroidal scaffold confers weak intrinsic androgenic activity and unique side effect profile (less estrogen-deprivation symptoms in some patients). Plasma half-life is approximately 24 hours; metabolism is hepatic via CYP3A4. Approved for adjuvant and metastatic ER-positive postmenopausal breast cancer. Used as the canonical steroidal suicide aromatase inhibitor in mechanism studies.

Mechanism of action

Irreversible suicide inactivation of aromatase via substrate-analog covalent adduction. Steroidal scaffold confers weak androgenic activity.

Reported research dose ranges

Clinical 25 mg in the published literature. Off-label use 12.5 to 25 mg. Rodent studies 1 to 10 mg/kg.

References

Lonning PE. Pharmacology of new aromatase inhibitors. Breast 1996.
Coombes RC, et al. Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study). Lancet 2007.
Buzdar AU, et al. An overview of the use of non-steroidal aromatase inhibitors in the treatment of breast cancer. Cancer 2002.

Read the full monograph

The full reference document is available as a research-use-only PDF download. Note: PDFs for newly added compounds may take a few hours to propagate after this article was published.

KDC-MN-278

The full reference document is provided strictly for research use only. It reports research dose ranges from the published literature, not instructions for use in humans or animals.

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Kodiac sells research compounds for investigative use only.

Exemestane

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Quick actions

Categories

Help and policies

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Adjacent monographs